MMCM
NVO

Murphy & Mullick Capital Management’s Novo Nordisk NVO Stock Holding History

Murphy & Mullick Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$214K Sell
5,813
-542
-9% -$25.7K 0.16% 130
2025
Q4 		$323K Buy
6,355
+378
+6% +$19.3K 0.23% 96
2025
Q3 		$331K Sell
5,977
-56
-0.9% -$3.28K 0.25% 89
2025
Q2 		$286K Sell
6,033
-119
-2% -$8.09K 0.23% 96
2025
Q1 		$427K Sell
6,152
-10
-0.2% -$826 0.41% 63
2024
Q4 		$530K Buy
+6,162
New +$666K 0.49% 50

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Murphy & Mullick Capital Management's NVO Position: Q1 2026 in Review

Murphy & Mullick Capital Management reduced its Novo Nordisk (NVO) stake by 8.5% in Q1 2026, selling an estimated $25.7K and leaving 5,813 shares worth $214K. The position accounts for 0.16% of the portfolio, ranked #130.

Murphy & Mullick Capital Management first reported a position in NVO in Q4 2024 and has held it in 6 quarters since. The position peaked at $530K in Q4 2024. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Murphy & Mullick Capital Management held 5,813 shares of Novo Nordisk worth $214K as of Q1 2026.
  • Murphy & Mullick Capital Management sold 542 Novo Nordisk shares in Q1 2026, an estimated $25.7K.
  • Novo Nordisk made up 0.16% of Murphy & Mullick Capital Management's portfolio in Q1 2026, its #130 holding.
  • Murphy & Mullick Capital Management first reported a position in Novo Nordisk in Q4 2024 and has held it in 6 quarters since.
  • Murphy & Mullick Capital Management's Novo Nordisk position peaked at $530K in Q4 2024.
  • 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q1 2026, filed 17 Apr 2026.